Schultz Kristofer, Wiehager Sara, Nilsson Karin, Nielsen Jørgen E, Lindquist Suzanne G, Hjermind Lena E, Andersen Birgitte B, Wallin Anders, Nilsson Christer, Petersén Asa
Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Neurosci Lett. 2009 Apr 3;453(2):104-6. doi: 10.1016/j.neulet.2009.02.008. Epub 2009 Feb 10.
Dementia with Lewy bodies (DLB) is the second most common form of neurodegenerative dementia after Alzheimer's disease (AD). The underlying neurobiological mechanism of DLB is not fully understood and no generally accepted biomarkers are yet available for the diagnosis of DLB. In a recent MRI study, DLB patients displayed hypothalamic atrophy whereas this region was not affected in AD patients. Cocaine and amphetamine regulated transcript (CART) is a neuropeptide expressed selectively in neurons in the hypothalamus. Here, we found that CSF CART levels were significantly reduced by 30% in DLB patients (n = 12) compared to controls (n = 12) as well as to AD patients (n = 14) using radioimmunoassay. Our preliminary results suggest that reduced CSF CART is a sign of hypothalamic dysfunction in DLB and that it may serve as a biomarker for this patient group.
路易体痴呆(DLB)是仅次于阿尔茨海默病(AD)的第二常见神经退行性痴呆形式。DLB的潜在神经生物学机制尚未完全明确,目前尚无普遍接受的生物标志物用于DLB的诊断。在最近的一项MRI研究中,DLB患者出现下丘脑萎缩,而该区域在AD患者中未受影响。可卡因和苯丙胺调节转录物(CART)是一种在下丘脑神经元中选择性表达的神经肽。在此,我们通过放射免疫分析法发现,与对照组(n = 12)以及AD患者(n = 14)相比,DLB患者(n = 12)的脑脊液CART水平显著降低了30%。我们的初步结果表明,脑脊液CART水平降低是DLB患者下丘脑功能障碍的一个标志,并且它可能作为该患者群体的生物标志物。